Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Darren Harvey is active.

Publication


Featured researches published by Darren Harvey.


European Journal of Medicinal Chemistry | 2013

Synthesis, structure–property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor

Peter Bach; Jonas Boström; Kay Brickmann; J.J.J. van Giezen; Robert D. Groneberg; Darren Harvey; Michael O'sullivan; Fredrik Zetterberg

The present paper describes the development of a new series of P2Y12 receptor antagonists based on our previously reported piperazinyl urea series 1 (IC50 binding affinity = 0.33 μM, aq solubility <0.1 μM, microsomal CLint (HLM) ≥300 μM/min/mg). By replacement of the urea functionality with a sulfonylurea group we observed increased affinity along with improved stability and solubility as exemplified by 47 (IC50 binding affinity = 0.042 μM, aq solubility = 90 μM, microsomal CLint (HLM) = 70 μM/min/mg). Further improvements in affinity and metabolic stability were achieved by replacing the central piperazine ring with a 3-aminoazetidine as exemplified by 3 (IC50 binding affinity = 0.0062 μM, aq solubility = 83 μM, microsomal CLint (HLM) = 28 μM/min/mg). The improved affinity observed in the in vitro binding assay also translated to the potency observed in the WPA aggregation assay (47: 19 nM and 3: 9.5 nM) and the observed in vitro ADME properties translates to the in vivo PK properties observed in rat. In addition, we found that the chemical stability of the sulfonylureas during prolonged storage in solution was related to the sulfonyl urea linker and depended on the type of solvent and the substitution pattern of the sulfonyl urea functionality.


Future Medicinal Chemistry | 2013

5-alkyl-1,3-oxazole derivatives of 6-amino-nicotinic acids as alkyl ester bioisosteres are antagonists of the P2Y12 receptor

Peter Bach; Jonas Boström; Kay Brickmann; Laurence E. Burgess; David Clarke; Robert D. Groneberg; Darren Harvey; Ellen R Laird; Michael O’Sullivan; Fredrik Zetterberg

BACKGROUND Recently, we reported ethyl nicotinates as antagonists of the P2Y12 receptor, which is an important target in antiplatelet therapies. A potential liability of these compounds was their generally high in vivo clearance due to ethyl ester hydrolysis. RESULTS Shape and electrostatic similarity matching was used to select five-membered heterocycles to replace the ethyl ester functionality. The 5-methyl and 5-ethyl-oxazole bioisosteres retained the sub-micromolar potency levels of the parent ethyl esters. Many oxazoles showed a higher CYP450 dependent microsomal metabolism than the corresponding ethyl esters. Structure activity relationship investigations supported by ab initio calculations suggested that a correctly positioned alkyl substituent and a strong hydrogen bond acceptor were necessary structural motifs for binding. In rat pharmacokinetics, the low clearance was retained upon replacement of an ethyl ester with a 5-ethyl-oxazole. CONCLUSION The use of shape and electrostatic similarity led to the successful replacement of a metabolically labile ethyl ester functionality with 5-alkyl-oxazole bioisosteres.


Archive | 2009

P38 inhibitors and methods of use thereof

Mark Munson; David A. Mareska; Youngboo Kim; Robert D. Gronenberg; James P. Rizzi; Martha Rodriguez; Ganghyeok Kim; Guy Vigers; Chang Rao; Devan Balachari; Darren Harvey


Archive | 2011

5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases

Mark Laurence Boys; Laurence E. Burgess; Robert Groneberg; Darren Harvey; Lily Huang; Timothy Kercher; Christopher F. Kraser; Ellen R. Laird; Eugene Tarlton; Qian Zhao


Archive | 2010

Piperidine-containing compounds and use thereof

Martha Rodriguez; David A. Mareska; Jeremy J. Hans; Darren Harvey; Robert Groneberg; Michael O'sullivan


Journal of Medicinal Chemistry | 2007

Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity

Derin C. D'amico; Toshi Aya; Jason Brooks Human; Christopher Fotsch; Jian Jeffrey Chen; Kaustav Biswas; Bobby Riahi; Mark H. Norman; Christopher A. Willoughby; Randall W. Hungate; Paul J. Reider; Gloria Biddlecome; Dianna Lester-Zeiner; Carlo Van Staden; Eileen Johnson; Augustus Kamassah; Leyla Arik; Judy Wang; Vellarkad N. Viswanadhan; Robert Groneberg; James Zhan; Hideo Suzuki; Andras Toro; David A. Mareska; David E. Clarke; Darren Harvey; Laurence E. Burgess; Ellen R. Laird; Benny C. Askew; Gordon Ng


Archive | 2006

Novel Pyridine Compounds

Peter Bach; Jonas Boström; Kay Brickmann; Leifeng Cheng; Fabrizio Giordanetto; Robert D. Groneberg; Darren Harvey; Michael O'sullivan; Fredrik Zetterberg; Krister Österlund


Archive | 2014

5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES

Mark Laurence Boys; Laurence E. Burgess; C. Todd Eary; Robert Groneberg; Bruno P. Hache; Darren Harvey; Erik James Hicken; Christopher F. Kraser; Ellen R. Laird; David Moreno; Mark Munson; Li Ren; John E. Robinson; Stephen T. Schlachter


Archive | 2004

P38 inhibitor und anwendungsverfahren dafür

Mark Munson; David A. Mareska; Youngboo Kim; Robert Groneberg; James P. Rizzi; Martha Rodriguez; Ganghyeok Kim; Guy Vigers; Chang Rao; Devan Balachari; Darren Harvey


Archive | 2017

imidazo[1,2-c]pirimidinas 5,7-substituídas

Bruno P. Hache; C. Todd Eary; Christopher F. Kraser; Darren Harvey; David Moreno; Ellen R. Laird; Erik James Hicken; John E. Robinson; Laurence E. Burgess; Li Ren; Mark Munson; Mark Laurence Boys; Robert Groneberg; Stephen T. Schlachter

Collaboration


Dive into the Darren Harvey's collaboration.

Researchain Logo
Decentralizing Knowledge